In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 197 for your search:
Cancer Type/Condition:  Leukemia, acute lymphocytic (ALL), child
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: UKALL2003, NCT00222612

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 1 to 14
Sponsor: Other
Protocol IDs: 2005-000658-56, 20040177, 2004-41-4276, NCT00192673

3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 and under
Sponsor: Other
Protocol IDs: LAL-BR/2001, NCT00526175

4.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and under
Sponsor: Other
Protocol IDs: LAL-AR-N-2005, NCT00526409

5.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0208, NCT00679536

6.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 and under
Sponsor: Other
Protocol IDs: 2007016, NCT00846703

7.

Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988

8.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: LAL Ph-2008, NCT01491763

9.

Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 0 to 18
Sponsor: Other
Protocol IDs: CHU-0060, NCT01007617

10.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 50
Sponsor: Other
Protocol IDs: HORCSCT-0902, NCT01015742

11.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: CDR0000686545, GPOH-COALL-08-09, EUDRACT-2009-012758-18, EU-21076, NCT01228331

12.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: GRASPALL2009-06, NCT01518517

13.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: CDR0000732604, COG-ANHL1131, ANHL1131, NCT01595048

14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to under 30
Sponsor: NCI, Other
Protocol IDs: AALL0433, COG-AALL0433, CDR0000495359, NCT00381680

15.

Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to under 22 at first relapse
Sponsor: NCI, Other
Protocol IDs: CDR0000500131, COG-ASCT0431, COG-PBMTC-ONCO51, ASCT0431, NCT00382109

16.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 and under at diagnosis
Sponsor: NCI, Other
Protocol IDs: CDR0000573996, COG-AALL0631, AALL0631, NCT00557193

17.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, 5R01CA140729, 5F32CA141762, R37CA036401, NCT00549848

18.

Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0307, NCT00619879

19.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: CDR0000613220, MOTOL-ALL-IC-BFM-2002, EU-20871, ALL-IC-BFM-2002, NCT00764907

20.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: NOPHO ALL2008 consolidation, NCT00816049

21.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 17
Sponsor: Other
Protocol IDs: NOPHO ALL2008 PEG Asparaginase, NCT00819351

22.

Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 18
Sponsor: Other
Protocol IDs: CCLG-ALLR3, CCLG-ALLR3, ISCRTN-45724312, EUDRACT-2004-000052-16, EU-20938, NCT00967057

23.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 30
Sponsor: Other
Protocol IDs: PRODECYTE, NCT00944008

24.

Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: AIEOP-BFM ALL 2009, NCT01117441

25.

Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: Under 35
Sponsor: Other
Protocol IDs: 2009-17, 2009-A00792-55, NCT01067300
1     
New Search